카스 번호:
h3292;sc7031;H 3292;H. 3292;Lispine;SC 7031;Isorythm;Ritmodan;Ritmilen;searle703
포뮬러 무게:
MOL 파일:


끓는 점
475.43°C (rough estimate)
1.0779 (rough estimate)
1.6300 (estimate)
저장 조건
Inert atmosphere,Room Temperature
Soluble in DMSO (25 mg/ml) and Ethanol (>35 mg/mL)
물리적 상태
산도 계수 (pKa)
10.2; also reported as 10.45(at 25℃)
6.17mg/L(22.5 ºC)
Stable for 1 year from date of purchase as supplied. Solutions in DMSO or ethanol may be stored at -20°C for up to 1 month.
CAS 데이터베이스
3737-09-5(CAS DataBase Reference)
  • 위험 및 안전 성명
  • 위험 및 사전주의 사항 (GHS)
위험품 표기 Xn,Xi,T,F
위험 카페고리 넘버 22-36/37/38-39/23/24/25-23/24/25-11
안전지침서 36-26-45-36/37-16-7
WGK 독일 3
RTECS 번호 UR8432000
HS 번호 2933.39.4100
독성 LD50 i.p. in mice: 517 mmol/kg (Ruenitz, Mokler)
기존화학 물질 KE-10945
그림문자(GHS): GHS hazard pictogramsGHS hazard pictograms
신호 어: Warning
유해·위험 문구:
암호 유해·위험 문구 위험 등급 범주 신호 어 그림 문자 P- 코드
H302 삼키면 유해함 급성 독성 물질 - 경구 구분 4 경고 GHS hazard pictograms P264, P270, P301+P312, P330, P501
H361 태아 또는 생식능력에 손상을 일으킬 것으로 의심됨 생식독성 물질 구분 2 경고 P201, P202, P281, P308+P313, P405,P501
P201 사용 전 취급 설명서를 확보하시오.
P308+P313 노출 또는 접촉이 우려되면 의학적인 조치· 조언를 구하시오.
NFPA 704
3 0

DISOPYRAMIDE C화학적 특성, 용도, 생산


Structurally, disopyramide does not belong to any of the known classes of antiarrhythmics; however, being a drug of the class IA sodium channel blockers, it exhibits membranestabilizing action and increases the effective refractory period and duration of an action potential in the atrium and ventricles. It causes a decrease in contractability and excitability of the myocardium, slowing of conductivity, and suppression of sinoatride automatism.

화학적 성질

Crystalline Solid


Disopyramide is used for preventing and restoring atrial and ventricular extrasystole and tachycardia in order to prevent atrial flutter and arrhythmia.


ChEBI: A monocarboxylic acid amide that is butanamide substituted by a diisopropylamino group at position 4, a phenyl group at position 2 and a pyridin-2-yl group at position 2. It is used as a anti-arrhythmia drug.


Disopyramide phosphate is used orally for the treatment of certain ventricular and atrial arrhythmias. Despite its structural dissimilarity to procainamide, its cardiac effects are very similar. Disopyramide is rapidly and completely absorbed from the gastrointestinal tract. Peak plasma level is usually reached within 1 to 3 hours, and a plasma half-life of 5 to 7 hours is common. Approximately half of an oral dose is excreted unchanged in the urine. The remaining drug undergoes hepatic metabolism, principally to the corresponding N-dealkylated form. This metabolite retains approximately half the antiarrhythmic activity of disopyramide and also is subject to renal excretion.

Clinical Use

Disopyramide (Norpace) can suppress atrial and ventricular arrhythmias and is longer acting than other drugs in its class.
The indications for use of disopyramide are similar to those for quinidine, except that it is not approved for use in the prophylaxis of atrial flutter or atrial fibrillation after DC conversion.The indications are as follows: unifocal premature (ectopic) ventricular contractions, premature (ectopic) ventricular contractions of multifocal origin, paired premature ventricular contractions (couplets), and episodes of ventricular tachycardia. Persistent ventricular tachycardia is usually treated with DC conversion.


The major toxic reactions to disopyramide administration include hypotension, congestive heart failure, and conduction disturbances. These effects are the result of disopyramide’s ability to depress myocardial contractility and myocardial conduction. Although disopyramide initially may produce ventricular tachyarrhythmias or ventricular fibrillation in some patients, the incidence of disopyramide-induced syncope in long-term therapy is not known. Most other toxic reactions (e.g., dry mouth, blurred vision, constipation) can be attributed to the anticholinergic properties of the drug.
CNS stimulation and hallucinations are rare.The incidence of severe adverse effects in long-term therapy may be lower than those observed with quinidine or procainamide.

Drug interactions

In the presence of phenytoin, the metabolism of disopyramide is increased (reducing its effective concentration) and the accumulation of its metabolites is also increased, thereby increasing the probability of anticholinergic adverse effects. Rifampin also stimulates the hepatic metabolism of disopyramide, reducing its plasma concentration.
Unlike quinidine, disopyramide does not increase the plasma concentration of digoxin in patients receiving a maintenance dose of the cardiac glycoside. Hypoglycemia has been reported with the use of disopyramide, particularly in conjunction with moderate or excessive alcohol intake.

주의 사항

Disopyramide should not be administered in cardiogenic shock, preexisting second- or third-degree A-V block, or known hypersensitivity to the drug. Neither should it be given to patients who are poorly compensated or those with uncompensated heart failure or severe hypotension. Because of its ability to slow cardiac conduction, disopyramide is not indicated for the treatment of digitalis-induced ventricular arrhythmias.
Patients with congenital prolongation of the QT interval should not receive quinidine, procainamide, or disopyramide because further prolongation of the QT interval may increase the incidence of ventricular fibrillation. Because of its anticholinergic properties, disopyramide should not be used in patients with glaucoma. Urinary retention and benign prostatic hypertrophy are also relative contraindications to disopyramide therapy. Patients with myasthenia gravis may have a myasthenic crisis after disopyramide administration as a result of the drug’s local anesthetic action at the neuromuscular junction.The elderly patient may exhibit increased sensitivity to the anticholinergic actions of disopyramide. Caution is advised when disopyramide is used in conjunction with other cardiac depressant drugs, such as verapamil, which may adversely affect atrioventricular conduction.

DISOPYRAMIDE 준비 용품 및 원자재


준비 용품


글로벌( 103)공급 업체
공급자 전화 이메일 국가 제품 수 이점
Shaanxi Dideu Medichem Co. Ltd
1006@dideu.com China 3965 58
TargetMol Chemicals Inc.
+1-781-999-5354 +1-00000000000
marketing@targetmol.com United States 19894 58
Career Henan Chemica Co
+86-0371-86658258 15093356674;
laboratory@coreychem.com China 30257 58
Shaanxi Dideu Medichem Co. Ltd
+86-29-29-89586680 +8618192503167
1006@dideu.com China 9804 58
Dideu Industries Group Limited
+86-29-89586680 +86-15129568250
Service@dideu.com China 29833 58
sgtlifesciences pvt ltd
dj@sgtlifesciences.com China 12382 58
Alfa Chemistry
Info@alfa-chemistry.com United States 21317 58
Shaanxi Didu New Materials Co. Ltd
+86-89586680 +86-13289823923
1005@dideu.com China 9645 58
+86-0576225566889 +86-13454675544
admin@jiuzhou-chem.com;jamie@jiuzhou-chem.com;alice@jiuzhou-chem.com China 21359 58
Mainchem Co., Ltd. +86-0592-6210733
sale@mainchem.com China 32362 55


Copyright 2019 © ChemicalBook. All rights reserved